C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

4.060 +0.160 (+4.10%)

Streaming Delayed Price Updated: 3:16 PM EDT, Aug 13, 2026 Add to My Watchlist

Price and Volume

Volume	2,989,235
Open	3.930
Bid (Size)	4.050 (3,000)
Ask (Size)	4.060 (1,000)
Prev. Close	3.900
Today's Range	3.860 - 4.230
52wk Range	1.690 - 5.170
Shares Outstanding	48,797,226
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+110.4%	+110.4%
1 Month	+3.6%	+3.6%
3 Month	+10.3%	+10.3%
6 Month	+121.9%	+121.9%
1 Year	+81.2%	+81.2%

More News

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

June 11, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Participate in Upcoming Conferences

May 20, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 12, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

April 09, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

March 25, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 09, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 26, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Participate in Upcoming March Conferences

February 23, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

February 23, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 09, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 26, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

January 14, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

November 25, 2025

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 06, 2025

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

October 16, 2025

From C4 Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 03, 2025

Via Benzinga

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

October 01, 2025

From C4 Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 22, 2025

Via Benzinga

Forecasting The Future: 4 Analyst Projections For C4 Therapeutics ↗

September 22, 2025

Via Benzinga

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025

From C4 Therapeutics, Inc.

Via GlobeNewswire

Why C4 Therapeutics Stock Crushed the Market on Monday ↗

September 15, 2025

Via The Motley Fool

Frequently Asked Questions

Is C4 Therapeutics, Inc. - Common Stock publicly traded?

Yes, C4 Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does C4 Therapeutics, Inc. - Common Stock trade on?

C4 Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for C4 Therapeutics, Inc. - Common Stock?

The ticker symbol for C4 Therapeutics, Inc. - Common Stock is CCCC on the Nasdaq Stock Market

What is the current price of C4 Therapeutics, Inc. - Common Stock?

The current price of C4 Therapeutics, Inc. - Common Stock is 4.060

When was C4 Therapeutics, Inc. - Common Stock last traded?

The last trade of C4 Therapeutics, Inc. - Common Stock was at 08/13/26 03:16 PM ET

What is the market capitalization of C4 Therapeutics, Inc. - Common Stock?

The market capitalization of C4 Therapeutics, Inc. - Common Stock is 198.12M

How many shares of C4 Therapeutics, Inc. - Common Stock are outstanding?

C4 Therapeutics, Inc. - Common Stock has 198M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.